|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:U.S._Food_and_Drug_Administration
2006
|
|
gptkbp:boosterRecommended
|
no
|
|
gptkbp:brand
|
gptkb:Gardasil
gptkb:Cervarix
gptkb:Gardasil_9
|
|
gptkbp:broadcastOn
|
2 or 3 doses
|
|
gptkbp:contains
|
virus-like particles
|
|
gptkbp:contraindication
|
severe allergic reaction to vaccine component
|
|
gptkbp:costEffectiveness
|
high
|
|
gptkbp:covers
|
over 100 countries
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
GlaxoSmithKline
|
|
gptkbp:duration
|
at least 10 years
|
|
gptkbp:excludes
|
gptkb:gene
live virus
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
HPV vaccines
|
|
gptkbp:includedIn
|
national immunization programs
|
|
gptkbp:notRecommendedFor
|
pregnant women
|
|
gptkbp:prevention
|
gptkb:cancer
anal cancer
human papillomavirus infection
genital warts
|
|
gptkbp:protectedBy
|
gptkb:HPV_type_11
gptkb:HPV_type_16
gptkb:HPV_type_18
gptkb:HPV_type_31
gptkb:HPV_type_33
gptkb:HPV_type_45
gptkb:HPV_type_52
gptkb:HPV_type_58
gptkb:HPV_type_6
|
|
gptkbp:recommendation
|
adolescents
preteens
|
|
gptkbp:reduces
|
gptkb:vaginal_cancer
penile cancer
vulvar cancer
oropharyngeal cancer
recurrent respiratory papillomatosis
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
pain at injection site
|
|
gptkbp:targetAudience
|
boys
girls
young adults
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:L1_protein
gptkb:HPV-16_L1_protein
gptkb:HPV-18_L1_protein
|
|
gptkbp:bfsLayer
|
7
|